

Press Release

For Immediate Release

Contact Person: Mihaela Melinte, Communication & PR Manager

E-mail: mihaela.melinte@antibiotice.ro

Phone: 0232.209.402

Iași, January 30, 2025

Excellence Continues: A Perfect 10 in the VEKTOR Ranking for Antibiotice Iași, Six Years in a Row

Antibiotice Iași has once again achieved a perfect 10 in the VEKTOR ranking for the sixth consecutive year, underscoring excellence in investor communication and engagement with the capital market. The evaluation included all companies listed on the Bucharest Stock Exchange (BSE), both on the main market and AERO market, each assessed based on specific criteria.

Antibiotice Iași continues to set standards of excellence in investor relations, securing a 10 out of 10 in the VEKTOR ranking, among 81 companies evaluated on the main market. This score reflects the quality of interaction and transparency of listed companies on the Bucharest Stock Exchange and is published annually on the BSE website.

VEKTOR is developed by the Romanian Investor Relations Association (RIRA) based on a methodology that includes 10 criteria assessing transparency, proactive investor communication, and corporate governance. Antibiotice has obtained the maximum score in all evaluation criteria, strengthening its reputation as a transparent and responsible company.

The performance achieved again in 2024 highlights Antibiotice's commitment to best practices in governance and investor communication.

A Strong Relationship with Investors: A Strategic Priority

Over the years, Antibiotice has proven that investor relations are not just a regulatory requirement but a strategic priority.

A key moment in its capital market dialogue has been the organization of “Investor Day” events. These gatherings brought together investors, financial analysts, and company representatives, providing an opportunity to explore growth strategies, investment projects, sustainability policies, and the company’s long-term perspectives.

“In an increasingly dynamic economic environment, transparency and strong governance are essential to our success in the capital market. Achieving the maximum VEKTOR score for the sixth consecutive year underscores our commitment to responsible governance and its integration into the company’s long-term strategy. We believe that strong governance is the foundation of investor confidence and sustainable development. Since 1997, when we were listed on the BSE, Antibiotice has traded over one billion shares, significantly contributing to the dynamics of Romania’s capital market. Through clear strategies and a sustainable vision, the company delivers value to both shareholders and the financial community”, stated Ioan Nani, CEO of Antibiotice Iași.

A Significant Contribution to Romania’s Capital Market

With nearly 28 years on the capital market, Antibiotice Iași (stock symbol ATB) remains a key player on the BSE. By the end of December 2024, the company recorded a market capitalization exceeding 1.7 billion lei, confirming the stability and attractiveness of its shares for investors, as well as the market’s confidence in its performance and development plans.

Looking Ahead

Antibiotice continues to strengthen its position on the Romanian capital market while also aiming to become a model of best practices and sustainability in the pharmaceutical industry.

Its commitment to transparency, corporate governance, and financial performance remains a key pillar of the company’s strategy.

Through innovative initiatives and an open dialogue with investors, Antibiotice proves that success in the capital market is built on trust, communication, and responsibility.